Episode 24: Overview of the Latest Guidance in IgA Nephropathy Management

Dr. Rizk is joined by Brad Rovin, MD (Ohio State University, United States), Co-Chair of the 2025 KDIGO IgAN/IgAV Guideline, for a deep dive into the latest updates in patient care. Their conversation explores the most important takeaways from the new guideline, the critical role of kidney biopsies in diagnosis and prognosis, the use of the IgAN prediction tool for risk assessment, and the updated thresholds and treatment goals designed to improve outcomes.

Episode 25: Treatment Revolution in IgA Nephropathy

Dr. Rizk is joined by Shikha Wadhwani, MD (Indiana University School of Medicine, United States), for a conversation on the treatment revolution in IgAN. They discuss how breakthroughs in understanding disease pathophysiology are fueling a wave of new therapies that go beyond traditional supportive care. Key topics include what’s changed since the KDIGO 2021 Guideline, the four-hit hypothesis and its role in driving novel therapies, key factors to consider when selecting treatments, and the evolving role of traditional approaches alongside newer agents.